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Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency
virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves
sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated
with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients
(1227) with CD4 cell counts 100/mm3 were enrolled in a randomized, double-blind trial. Valaci-
clovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms
were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipi-
ents and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV
disease was significantly longer for the valaciclovir group (P  .03). A trend toward earlier mortality
for valaciclovir recipients was seen (P  .06). Toxicity and earlier medication discontinuation were
more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further
exploration of a better-tolerated dose is warranted.
Cytomegalovirus (CMV) end-organ disease, especially reti- retinitis, which accounts for 80% of end-organ disease [2],
nitis, is a common serious complication of advanced human causes retinal necrosis and may progress to blindness. Treat-
immunodeficiency virus (HIV) infection, affecting 25%– ment of established disease requires lifelong parenteral or intra-
40% of those with very low CD4 cell counts [1–3]. CMV ocular administration of virustatic agents (ganciclovir, foscar-
net, and recently, cidofovir) that are toxic and expensive.
Despite treatment, progression of retinal lesions typically oc-
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of 18 pills per day. All medications considered essential for optimaldaily, which is sufficient to inhibit many clinical strains of
care were permitted, except anti-CMV agents and immunomodula-CMV [9].
tors. Simultaneous enrollment in other studies of HIV disease man-Oral acyclovir prophylaxis for recurrent herpes simplex virus
agement was encouraged.(HSV) infections is commonly used in patients with advanced
Design and study conduct. Comparison of the valaciclovir armHIV disease. Two prospective randomized studies of such pa-
with the pooled acyclovir arms for the prevention of CMV end-
tient populations have shown a survival advantage associated
organ disease, provided the acyclovir arms were not different, was
with high-dose acyclovir compared with placebo [10, 11] but specified in the protocol. The higher acyclovir dose (3.2 g/day)
no significant effect on the development of CMV disease, and had been shown in two previous placebo-controlled trials to be
a third study failed to demonstrate an effect on CMV cultures ineffective for preventing CMV disease in patients with advanced
[12]. Retrospective studies have demonstrated discordant re- HIV infection [10, 11], and it was anticipated that the lower dose
of acyclovir would also be ineffective. The 3.2 g/day dose wassults on mortality with acyclovir use [13, 14]. It is possible
associated with a survival advantage in these studies, so investiga-that clinically silent herpesvirus replication may up-regulate
tion of the effect of both lower and higher delivered doses ofHIV replication [15, 16], an effect that could be mitigated by
acyclovir was planned to explore a possible dose-effect relation-acyclovir.
ship. This analysis would compare the survival experience of theWe conducted a randomized, double-blind, comparative
three arms in pairwise fashion. A target sample size of 1200 pa-study of valaciclovir, 2 g four times daily, and two doses of
tients, with 12 months of planned follow-up after entry of the last
oral acyclovir for the prevention of CMV end-organ disease
subject, was selected to provide at least 82% power to detect an
and mortality in persons with advanced HIV disease. A phar- approximate doubling of the median CMV-free time for valaci-
macokinetic study defined this valaciclovir dose as the maxi- clovir relative to the pooled acyclovir arms and to detect a 55%
mum tolerated dose in AIDS patients [8]. A high dose of increase in median survival for pairwise comparison among the
acyclovir, 800 mg four times daily, was the dose used in the three arms.
Participants were evaluated at baseline, week 4, and week 8 andplacebo-controlled trials that reported a survival benefit without
every 8 weeks thereafter. At each visit, blood was obtained foraffecting CMV disease incidence [10, 11]. A lower dose, 400
routine laboratory tests, serum and plasma specimens were banked,mg twice daily, was chosen to suppress HSV recurrences and
urine was cultured for CMV according to local methods, and qual-to prevent possible unblinding that might occur with a placebo.
ity-of-life measures were assessed. CD4 cell counts and HIV p24Use of three different delivered doses of acyclovir permitted
antigen determinations were obtained every 24 weeks.exploration of a possible dose-effect relationship on survival.
As this was a collaborative effort of the AIDS Clinical Trials
Group (ACTG) and investigators in Europe, Canada, and Australia,
an International Steering Committee was formed with appropriateMethods
representation. The committee met semiannually and provided
overall governance to the diverse study sites.Subjects. Eligible subjects were ⁄13 years old, with labora-
tory evidence of HIV infection or a clinical diagnosis of AIDS, Dose modification and toxicity management. Since acyclovir
is generally well-tolerated, even by patients with advanced HIVan absolute CD4 lymphocyte count100/mm3, serologic evidence
of prior CMV infection, a Karnofsky performance score ⁄60, and disease, study drug dosing was modified only for diminished renal
function (estimated creatinine clearance,50 mL/min) that wouldno evidence of CMV end-organ disease. All participants were
evaluated for possible retinitis within 21 days before entry by an impair acyclovir elimination. When significant toxicity (grade 3 or
higher according to the standard ACTG toxicity grading scheme)experienced ophthalmologist who used dilated indirect fundos-
copy. Patients with symptoms associated with extraocular CMV occurred, a trial of interruption, dose reduction, or discontinuation
was advised for potentially toxic nonstudy medications. If thesyndromes were required to undergo additional medical evaluation
as indicated to rule out preexisting CMV disease. Participants had toxicity did not resolve, study drug was then interrupted. If toxicity
attributed to study drug did not resolve within 30 days, studyto be receiving all medications for HIV and opportunistic infec-
tions for at least 30 days before entry; there were no restrictions medication was permanently discontinued until a protocol amend-
ment (July 1994) allowed patients to restart study drug after anon these therapies.
Patients were ineligible if they had chronic nausea or vomiting, interruption of up to 6 months for any reason. Study drug formula-
tion included 3.6, 10.9, and 13.4 g of lactose/day for valaciclovir,ocular media opacities, or necrotizing retinopathy, were pregnant
or breast-feeding, had a history of hypersensitivity to acyclovir or high-dose acyclovir, and low-dose acyclovir, respectively. Symp-
toms suggestive of lactose intolerance were managed with dietaryknown lactose intolerance, had received immunomodulators within
30 days before entry, had previously received anti-CMV agents, modification or a trial of lactase (or both).
CMV disease end-point evaluations. Study ophthalmologistsor had any of the following laboratory values: absolute neutrophil
count 500/mm3, estimated creatinine clearance 50 mL/min, performed dilated indirect funduscopy in all subjects every 24
weeks and whenever new visual complaints arose. Retinal photo-total bilirubin5 mg/dL, or serum aminotransferase5 times the
upper limit of normal. graphs were taken to document CMV retinitis and were verified
by an independent fundus photograph reading center that wasRandomization and treatment. Participants were randomized
in a 3:2:2 ratio to valaciclovir, 2 g four times daily, high-dose masked to study drug assignment. Participants were evaluated at
both scheduled and symptom-driven visits for signs and symptomsacyclovir, 800 mg four times daily, or low-dose acyclovir, 400 mg
twice daily. Patients were stratified by baseline CD4 cell count: of possible extraocular CMV disease by use of a standardized
questionnaire. Additional medical assessment was directed by the50 and 50–100/mm3. Double-blinding required administration
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site investigator. Diagnostic criteria for confirmed extraocular dis- dose acyclovir, and low-dose acyclovir, respectively) or by
ease, as defined in the protocol, were based on a compatible clinical drug (7.1% for valaciclovir and 6.1% for acyclovir) were
syndrome with histologic evidence of invasive CMV disease. Data similar.
pertaining to all extraocular disease, including presentation, radio- CMV disease end points. One hundred eighty-four patients
logic evaluation, and results of diagnostic procedures and labora- (15% overall) had confirmed CMV end-organ disease (table
tory testing, were reviewed by an international committee of seven
2). Forty-eight patients (3.9%) had end points reported that
investigators blinded to site and study drug assignment. Neither
could not be confirmed because of missing critical data, suchCMV viremia nor a positive culture from any site without clinical
as retinal photographs or tissue histology. Eighteen end pointsand histologic evidence of invasive disease was considered an end
(1.5%) were rejected because they failed to meet predefinedpoint.
criteria; all but 2 of these were cases of extraocular disease.Statistical methods and interim analyses. Primary analyses in-
cluded all eligible participants according to their randomized treat- Most confirmed end points (77.2%) occurred in patients with
ment assignment (intent-to-treat principle). The Kruskal-Wallis 50 CD4 cells at entry.
test was used for comparisons of ordinal data and the x2 test for The valaciclovir arm was compared with the two pooled
nominal data. Product-limit estimates were used to summarize acyclovir arms for prevention of CMV disease, according to
time-to-event data [17]. The log rank test was used for comparing the protocol, because the two acyclovir arms were similar
time-to-event distributions [18, 19]. Cumulative incidence analysis (P  .67). The confirmed end-point rates were 11.7% and
was done to assess the risk of developing CMV disease in the face
17.5% for valaciclovir and acyclovir, respectively, representing
of competing mortality [20]. All tests of significance were two-
a 33% reduction for those randomized to valaciclovir. Timesided. All P values reported are nominal P values, unadjusted for
to confirmed CMV disease was significantly longer for theinterim analyses or for multiple comparisons.
valaciclovir group than for those assigned to acyclovir (PThe study was monitored by an independent data and safety
 .03; figure 1). The hazard ratio (HR) for valaciclovir relativemonitoring board, following an O’Brien-Fleming group sequential
approach [21]. At the third scheduled interim analysis for efficacy, to acyclovir was 0.71 (95% confidence interval [CI], 0.52–
with 57% of the total end points reported, significantly earlier 0.97), consistent with a significant reduction in the risk for
mortality was seen in the valaciclovir arm, with only a trend toward CMV disease. The estimated 12-month rates for confirmed end
a CMV preventive effect. The study was terminated at that time, points were 10% for valaciclovir and 14.6% for acyclovir.
with all follow-up visits completed by May 1995 and data collec- A number of secondary analyses were done. When all re-
tion completed by August 1995. ported (confirmed plus presumptive) end points were consid-
ered, the protective effect of valaciclovir in delaying time to
first CMV disease persisted (P  .009; table 2). ConsideringResults
only the 122 end points (66%) that occurred while participants
were receiving assigned study medication or within 14 daysStudy population. Enrollment of 1227 subjects at 72 sites
began in December 1992 and ended in October 1994. Sixty- of its discontinuation (as-treated analysis), valaciclovir was
significantly more effective than acyclovir (P  .006). In asix percent were enrolled at ACTG sites in the United States
and 34% at sites in Canada, Australia, and Europe. Seventy cumulative incidence analysis of CMV end points that ac-
counted for the competing risk of death, valaciclovir signifi-participants (5.7%) had 73 eligibility exemptions, primarily for
laboratory values out of range or out of date. Participants were cantly reduced the risk of CMV disease relative to acyclovir
(P  .006).primarily white, non-Hispanic (79.8%) men (93.9%) who had
never injected drugs (92.3%). The treatment arms were compa- Baseline positive urine cultures were predictive of future
CMV disease. Seventy-nine CMV end points (23.9%) occurredrable with respect to selected baseline characteristics (table 1).
Fewer than half (44.6%) had urine cultures positive for CMV among those with positive cultures at entry, whereas only
46 (11.2%) occurred among those with negative cultures (Pat entry. The median CD4 cell count was 32/mm3, and 67.9%
had 50 cells/mm3. Prophylaxis for Pneumocystis carinii  .001). In multivariate analyses that included baseline demo-
graphics, laboratory values, urine culture results, time of urinepneumonia, Mycobacterium avium complex (MAC) infection,
and fungal infections were used by 96.5%, 26.2%, and 53.3%, culture conversion, other diagnoses, and antiretroviral use, va-
laciclovir was significantly protective (P  .05). A greaterrespectively, and was balanced among the arms. There were
no significant differences in the use of one or more antiretrovi- protective effect was seen in the higher CD4 cell count stratum
(⁄50) at entry, with rates of 4% and 16%, respectively, forral agents (zidovudine, didanosine, zalcitabine, stavudine, or
nevirapine), taken by 79.2% overall, or for prior diagnoses of valaciclovir and the pooled acyclovir arms (P  .001) com-
pared with 15% and 18%, respectively, for those with entryHSV or varicella-zoster virus infection, Kaposi’s sarcoma,
P. carinii pneumonia, or disseminated MAC infection. The CD4 cell count 50 (P  .57).
CMV retinitis accounted for 79.3% of end points and gastro-median duration of study treatment was 29, 36, and 40 weeks
for valaciclovir, high-dose acyclovir, and low-dose acyclovir, intestinal disease for 15.2%; other diagnoses were relatively
infrequent (table 3). Despite small numbers, a proportionalrespectively; however, the median duration of follow-up was
comparable at 57, 56, and 60 weeks. Loss to follow-up rates reduction in all CMV diagnoses was seen for valaciclovir.
There were no significant differences among the arms withby study arm (7.1%, 7.9%, and 4.3% for valaciclovir, high-
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Table 1. Selected baseline characteristics of patients with advanced HIV infection participating in
valaciclovir CMV prophylaxis study.
VACV HACV LACV Total
(n  523) (n  353) (n  351) (n  1227) P*
Male (%) 93.9 94.3 93.4 93.9 0.89
Age, years (median) 38 37 37 37 0.42
Race/ethnicity (%)
White, non-Hispanic 80.3 81.0 77.8 79.8 0.57
Black, non-Hispanic 11.7 9.9 11.4 11.1
Hispanic 5.7 7.4 9.1 7.2
Other 2.3 1.7 1.7 2.0
No injection drug use (%) 92.5 92.4 91.7 92.3 0.91
Karnofsky score (median) 90 90 90 90 0.59
CD4 cells/mm3 (median) 31 33 33 32 0.95
% with 50/mm3 66.9 68.6 68.7 67.9
Hemoglobin ⁄7 g/dL (%) 99.2 99.4 98.9 99.2 0.29
Urine CMV culture-positive (%)† 48.9 42.5 40.1 44.6 0.10
Any antiretroviral use 78.2 79.9 80.1 79.2 0.75
Prophylaxis (%)
PCP 96.7 96.3 96.3 96.5 0.92
MAC 27.2 23.5 27.6 26.2 0.38
Fungal 53.5 52.7 53.6 53.3 0.96
Prior diagnosis (%)
HSV or VZV 45.5 45.6 44.7 45.3 0.97
Kaposi’s sarcoma 14.0 10.2 11.7 12.2 0.23
PCP 26.8 26.1 26.5 26.5 0.97
MAC 5.7 7.6 5.7 6.3 0.45
NOTE. VACV valaciclovir; HACV high-dose acyclovir; LACV low-dose acyclovir. PCP Pneumocystis
carinii pneumonia; MAC  Mycobacterium avium complex; HSV  herpes simplex virus; VZV  varicella zoster
virus.
* All tests of significance were Pearson’s x2 test, except for age, CD4 cell count (Kruskal-Wallis test).
† Based on total of 742 evaluable cultures: VACV, 323; HACV, 212; LACV, 207.
regard to the development of varicella-zoster virus or HSV among the 411 patients who were culture-negative at entry
(P .001) and decreased the duration of viral shedding amonginfections or for new diagnoses of Kaposi’s sarcoma.
Antiviral activity. The effect of valaciclovir on recovery of the 331 who were culture-positive at entry (P  .003; figure
2). Although viral shedding may be intermittent in the absenceCMV from urine cultures was analyzed according to whether
the baseline culture result was negative or positive. Valaciclovir of specific anti-CMV therapy, these results suggest that valaci-
clovir had a greater antiviral effect than acyclovir. Antiviralboth significantly delayed the time to first positive culture
Table 2. CMV disease end points in patients with advanced HIV
infection: valaciclovir versus pooled acyclovir groups.
VACV HACV / LACV* Total
End point (n  523) (n  704) (n  1227)
Reported 83 (16.8) 167 (23.7) 250 (20.4)†
Confirmed‡ 61 (11.7) 123 (17.5) 184 (15.0)
Rejected 4 (0.8) 14 (2.0) 18 (1.5)
Unevaluable 18 (3.4) 30 (4.3) 48 (3.9)
NOTE. Data are no. (%). VACV  valaciclovir; HACV  high-dose
acyclovir; LACV  low-dose acyclovir.
* Planned analysis for efficacy of prophylaxis was comparison of VACV
with pooled ACV arms.
Figure 1. Kaplan-Meier plot of time to first confirmed CMV end-† 29 patients had multiple end points reported, for total of 285 CMV end
organ disease in valaciclovir CMV prophylaxis study. Valaciclovirpoints.
(VACV) significantly delayed time to first confirmed CMV disease‡ Only patients’ first confirmed end point was considered for primary analy-
sis. compared with pooled acyclovir (ACV) arms (P  .03, log rank test).
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Table 3. Distribution of CMV syndromes among participants with
confirmed end points in CMV prophylaxis trial.
VACV HACV / LACV Total
Syndrome (n  523) (n  704) (n  1227)
Retinitis 51 (9.75) 95 (13.5) 146 (11.9)
Upper GI disease* 4 (0.8) 11 (1.6) 15 (1.2)
Lower GI disease† 3 (0.6) 10 (1.4) 13 (1.1)
CNS disease‡ 2 (0.4) 7 (1.0) 9 (0.7)
Pneumonitis 1 (0.2) 0 (0.0) 1 (0.1)
NOTE. Data are no. (%). VACV  valaciclovir; HACV  high-dose
acyclovir; LACV low-dose acyclovir. GI, gastrointestinal tract; CNS, central
nervous system.
* Mouth ulcer, esophagitis, gastritis, duodenitis.
Figure 3. Kaplan-Meier plot of time to death. For survival, each† Colitis, proctitis.
treatment arm was compared with other 2 arms. There was trend to‡ Encephalitis, radiculomyopathy.
earlier mortality in valaciclovir (VACV) group (P  .06, log rank
test) compared with high- and low-dose acyclovir (HACV, LACV).
activity as assessed by polymerase chain reaction is described
in the companion paper by Griffiths et al. [22]. rates of 24.1%, 19.5%, and 18.8%. Pairwise comparisons sug-
Survival. There were 488 deaths overall (39.8%). A trend gested that the risk of death was greater for valaciclovir than
toward earlier mortality was seen for patients randomized to for low-dose acyclovir (HR, 1.28; 95% CI, 1.03–1.59), with
valaciclovir (P  .06; figure 3). Mortality rates were 42.6%, no significant difference between valaciclovir and high-dose
38.2%, and 37.0% for valaciclovir, high-dose acyclovir, and acyclovir (HR, 1.17; 95% CI, 0.94–1.45) or between the two
low-dose acyclovir, respectively, with estimated 12-month acyclovir arms (HR, 1.10; 95% CI, 0.87–1.40).
Only 57 deaths (11.7%) occurred in patients who were still
receiving assigned study medication or within 14 days of its
discontinuation. In an as-treated analysis, survival was signifi-
cantly shorter in the valaciclovir arm (P  .002). Mortality
was similar among those who had positive or negative urine
CMV cultures at entry, with 137 (41.4%) and 148 (36.0%)
deaths, respectively (P  .13). Multivariate analyses revealed
an increased risk of death in patients receiving valaciclovir
when baseline demographics, laboratory values, diagnoses,
antiretroviral use, and time of elevated serum creatinine were
considered (P  .05).
The most common principal cause of death, in 44 patients
(9.0% of all deaths), was non-Hodgkin’s lymphoma, evenly
divided between systemic and primary central nervous system
disease. Other common causes of death were non–P. carinii
pneumonia (8.8%), disseminated MAC infection (8.6%), wast-
ing (7.8%), P. carinii pneumonia (7.4%), sepsis (6.8%), and
Kaposi’s sarcoma (6.6%). CMV disease was listed as the prin-
cipal cause of death for 16 patients (3.3%). There were no
significant differences in the primary causes of death among
the three arms.
Tolerance. Of all adverse events grade 3 or higher, only
gastrointestinal complaints occurred significantly more often
and earlier in the valaciclovir arm (P  .03). Grade 2 or greater
increases in serum creatinine (1.5 times the upper limit of
normal) occurred earliest in the valaciclovir group (P  .03),
although there were no differences among the arms for grade
1 or higher increases (P  .11). Sixty-five patients had an
Figure 2. Antiviral effect of valaciclovir (VACV) on recovery of
estimated creatinine clearance 50 mL/min while receivingCMV from urine compared with pooled acyclovir (ACV) arms ac-
study medication; 58.5% were randomized to valaciclovircording to baseline culture status (A, culture-negative; B, culture-
positive). (P  .03).
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Eighteen patients developed an illness with features sugges- controlled trial using the same dose of ganciclovir failed to
confirm this result [25]. Secondary analyses that included pre-tive of thrombotic microangiopathy (TMA), reported as throm-
bocytopenic purpura or hemolytic-uremic syndrome, 8 of sumptive diagnoses and end points that occurred while patients
were receiving treatment or within 14 days of its discontinua-whom were still receiving assigned study medication. Most
cases failed to meet established criteria for classical thrombocy- tion, as well as evidence of an antiviral effect on recovery
of virus from urine, support the superiority of valaciclovir intopenic purpura or hemolytic-uremic syndrome, with milder
thrombocytopenia and anemia, rare neurologic abnormalities, delaying CMV disease compared with acyclovir.
This is the first randomized trial of CMV prophylaxis inpoor response to plasma therapy when administered, and pro-
longed survival without plasma therapy. The reported events which all end points were independently confirmed. Cases of
retinitis were evaluated by an independent retinal photographoccurred a median of 54 weeks after enrollment (range, 8–84).
TMA-like syndromes were reported more frequently in the reading center, and extraocular disease was assessed by a panel
of blinded investigators. Protocol criteria for confirmed extra-valaciclovir arm (14) than in either of the acyclovir arms (high-
dose acyclovir, 1; low-dose acyclovir, 3; P  .008). Those ocular disease were stringent, requiring a compatible clinical
syndrome and evidence of CMV-related tissue invasion. Forty-randomized to valaciclovir had received doses of 8 g/day for
a median of 54 weeks (range, 8–77), and 12 had been treated eight patients who received a clinical diagnosis of CMV end-
organ disease lacked key data for independent confirmation,for 35 weeks. Patients with TMA-like syndromes received
multiple medications, and most had intercurrent illnesses that and 18 cases that were fully evaluated failed to meet predeter-
mined criteria. Sixteen of these were presumptive diagnoses ofcould explain the hematologic and renal abnormalities. The
relative risk of a TMA-like event was increased among recipi- extraocular disease, which may reflect the difficulty in estab-
lishing an unequivocal diagnosis in clinical practice or the strictents of a number of concomitant medications, including clofazi-
mine, fluconazole, ciprofloxacin, ethambutol, and trimetho- case definitions used. In contrast, clinical diagnosis of CMV
retinitis by experienced ophthalmologists appears sufficient forprim-sulfamethoxazole, as well as valaciclovir. These cases
and associated risk factors are more fully described else- future trials.
A trend to earlier mortality was seen in the valaciclovirwhere [23].
Treatment discontinuation. The treatment arms differed in group compared with the acyclovir arms. Two randomized
double-blind trials that compared high-dose acyclovir with pla-time to permanent discontinuation of study medication for rea-
sons other than death or the development of CMV disease, cebo in patients with advanced HIV disease (median CD4 cell
count, 39 and 32/mm3) reported annual mortality estimates ofwith those assigned to valaciclovir discontinuing earlier (P
 .01). The overall estimated 12-month discontinuation rate 23% and 27% for the high-dose acyclovir recipients compared
with 39% and 46%, respectively, for the placebo groupswas 46.6%. The respective rates for valaciclovir, high-dose
acyclovir, and low-dose acyclovir were 50.5%, 46.2%, and [10, 11]. The current study, which lacked a placebo arm, had
similar annual mortality rates, with 18.8%, 19.5%, and 24.1%41.0%. Patients randomized to valaciclovir discontinued dos-
ing significantly more often for protocol-defined toxicity (P for low-dose acyclovir, high-dose acyclovir, and valaciclovir,
respectively. Differences that may have an impact on mortality, .001), with a trend toward earlier discontinuation for subjec-
tive complaints (P  .07), while those assigned to acyclovir such as baseline HIV load, are not available. Patients with less
advanced HIV disease (CD4 cell count, 100–300/mm3) treateddiscontinued treatment significantly more often for the develop-
ment of CMV disease (P  .001). Participants cited pill burden with high-dose acyclovir or placebo for a median of 365 days
had no difference in survival, although median time to death(8.4%) and gastrointestinal complaints (7.1%) as their most
common reasons for self-initiated discontinuation, with no sig- was long (945 days) [26]. Additional support for the concept
that inhibition of herpesvirus replication may improve survivalnificant differences among the arms.
in AIDS has come from a recent well-designed observational
study [14], although a second observational study did not find
Discussion
a survival advantage [13]; this discordance may result from
methodologic concerns [27]. Two placebo-controlled studiesThis study was designed to compare valaciclovir, 2 g four
times daily, with high- and low-dose acyclovir (arms com- of oral ganciclovir prophylaxis for CMV disease demonstrated
a trend to enhanced survival for ganciclovir recipients [24, 25].bined) for the prevention of CMV disease in patients with
advanced HIV infection and for pairwise comparison of the The results of the study reported here may provide some
insight into which herpesviruses are responsible for this effect.three different delivered acyclovir doses for survival. A sig-
nificant protective effect for valaciclovir against CMV disease As there was no significant difference between high- and low-
dose acyclovir, improved survival may be due to suppression ofwas demonstrated, with a 33% reduction in the rate of con-
firmed CMV end-organ disease and significant prolongation of the most sensitive herpesviruses, such as HSV-1 or -2. Further
support for this possibility comes from evidence that HSVthe time to development of CMV disease (P  .03). A 49%
reduction in the rate of confirmed CMV end-organ disease has infection in human skin is associated with increased numbers
of HIV virions, possibly HIV/HSV pseudotypes, and that reac-previously been demonstrated in a placebo-controlled study of
oral ganciclovir, 1 g three times daily [24]. A second placebo- tivation of HSV-2 can increase HIV plasma RNA levels [28,
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Andersen (Harvard School of Public Health) with additional statis-29]. However, the possible involvement of other herpesviruses,
tical analyses. This study is dedicated to the memory of Gareysuch as Epstein-Barr virus or human herpesvirus 8, cannot be
Lambert—friend, advisor, patient advocate, and study partici-discounted.
pant—whose counsel and wit were never-failing and whose lossThere was an association between treatment with valaci-
is deeply mourned.clovir and moderate nephrotoxicity. Although the time to grade
3 or greater renal impairment was not significantly different
among the arms, there was a difference for more modest impair- References
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